Big News! (STGI) Steroidogenesis Shares ApprovedFor Trading on the Berlin Stock Exchange Under the Symbol SSJ
April 29, 1999 05:15 PM
LAS VEGAS--(BW HealthWire)--April 29, 1999--Steroidogenesis Inhibitors International STGI today reported it has been informed by the DEUTSCHE BORSE AG, the German stock market, that, STGI shares have been approved for trading on the Berlin Stock Exchange, the Third Market Segment, under the symbol SSJ, and the German securities code (WERTPAPIERKENN NUMMER) No. 920 436.
Commenting on the listing, Dr. Alfred Sapse, STGI President said, "We are pleased that large numbers of potential investors highly interested in health issues will gain access to our shares and STGI." Sapse noted that STGI's documentation to become a reporting company in the U.S. will be filed with the SEC in mid-May.
The Company also noted it was informed that Michael Jackson's interview (paid program) with Drs. Sapse and Greeson, will be transmitted through CNBC, May 23, 1999, with German voice over/translation, to Switzerland, Germany and Austria. Drs. Sapse and Greeson will be in Berlin and other European locations, May 18-25, 1999 where they will meet with market analysts, members of the financial community and a pharmaceutical company.
STGI is a pharmaceutical R&D Corporation, engaged in the development of anticortisol drugs to be used in diseases/conditions associated with elevated levels of the immunosuppressive hormone cortisol. STGI's flagship anticortisol drug, ANTICORT, has been approved by the FDA in the U.S. and by its Canadian and Romanian counterparts to be clinically tested in an HIV adult and children populations - a condition often associated with "high cortisol" that is apparently playing a major role in the destruction of the immune system as encountered in HIV+ and AIDS.
Satellite clinical studies are being planned in the U.S. and abroad in the treatment of treatment resistant depression, anorexia nervosa, also in a condition afflicting large numbers of 60+ population, as well as in immune deficient/suppressed diseases such as cancers of breast and prostate. Experimental studies are being carried out in collaboration with two major U.S. Universities looking into the potential role of Anticort in the prevention of retinitis pigmentosa in a transgenic group of mice.
This release may include "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable. For more information visit our World Wide Web page at www.anticort.com. |
